1. A therapeutic pharmaceutical composition comprising
(a) an analgesic;
(b) a gel forming polymer;
(c) a nasal tissue irritant; and
(d) an emetic in sufficient amount to cause emesis if greater than a prescribed amount of the analgesic of the therapeutic composition is ingested.
2. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in unit dose form.
3. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.
4. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic comprises an opioid analgesic present in an amount of about 5 mg to about 200 mg on a solid weight basis.
5. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic comprises hydrocodone or a therapeutically acceptable salt thereof.
6. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic comprises oxycodone or a therapeutically acceptable salt thereof.
7. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic comprises morphine or a therapeutically acceptable salt thereof.
8. The therapeutic pharmaceutical composition of claim 1, wherein the analgesic is selected from the group consisting of alfentanil, amphetamines, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diphenoxylate, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, \u03b2-hydroxy-3-methylfentanyl, levo-\u03b1-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, methylphenidate, morphine, nalbuphine, nalmefene, o-methylnaltrexone, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine and tramodol, or therapeutically acceptable salts thereof.
9. The therapeutic composition of claim 1, wherein the gel forming polymer comprises one or more of polyethylene oxide having average molecular weight ranging form about 300,000 to about 5,000,000, polyvinyl alcohol having a molecular weight of about 20,000 to 200,000, hydroxypropyl methyl cellulose having a molecular weight of about 10,000 to 1,500,000, and a carbomer having a molecular weight ranging of about 700,000 to 4,000,000,000.
10. The therapeutic composition of claim 1, wherein the gel forming polymer comprises one or more of polyethylene oxide having a viscosity in the range from about 8,800 to about 17,600 cps., polyvinyl alcohol having a viscosity in the range from about 4 to about 65 cps., hydroxypropyl methyl cellulose having a viscosity in the range from about 3600 to about 5600 cps., and a carbomer having a viscosity in the range from about 4000 to about 39,400 cps.
11. The therapeutic composition of claim 1, wherein the gel forming polymer comprises polyvinyl alcohol.
12. The therapeutic composition of claim 1, wherein the gel forming polymer comprises hydroxypropyl methyl cellulose.
13. The therapeutic composition of claim 1, wherein the gel forming polymer comprises polyethylene oxide.
14. The therapeutic composition of claim 1, wherein the nasal tissue irritating amount of a surfactant includes 1 to 5 percent by weight of one or more of poloxamer, sorbitan monoesters, glyceryl monooleates and sodium lauryl sulfate.
15. The therapeutic composition of claim 1, wherein the nasal tissue irritating amount of a surfactant includes 1 to 5 percent by weight sodium lauryl sulfate.
16. The therapeutic composition of claim 1, wherein the emetic comprises zinc sulfate at about 5 to 25 percent by weight on a solid basis.
17. A method of making a therapeutic composition suitable for deterring drug abuse comprising
(a) providing an drug, a gel forming polymer having a viscosity, a nasal tissue irritant and emetic;
(b) controlling the molecular weight or viscosity of the gel forming polymer;
(c) controlling the amount of nasal tissue irritant such that nasal tissue irritation occurs if inhaled;
(d) controlling the amount of emetic such that emesis ensues only if more than a prescribed amount of the drug is consumed; and
(e) combining the analgesic, gel forming polymer, nasal tissue irritant and emetic to form a therapeutic composition;
wherein the composition deters abuse of the analgesic by forming a viscous gel upon contact with a solvent; inducing nasal irritation if inhaled, and inducing emesis if more than a prescribed amount of the analgesic is consumed.
18. The method of claim 17, further comprising the step of processing the composition into a unit dose form.
19. The method of claim 17, further comprising the step of processing the composition into a suppository, capsule, caplet, pill, or a direct compressed tablet form.
20. The method of claim 17, wherein the drug comprises an opioid analgesic.
21. The method of claim 17, wherein the drug is selected from the group consisting of alfentanil, amphetamines, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diphenoxylate, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, \u03b2-hydroxy-3-methylfentanyl, levo-\u03b1-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, methylphenidate, morphine, nalbuphine, nalmefene, o-methylnaltrexone, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine and tramodol, or therapeutically acceptable salts thereof.
22. The method of claim 17, wherein the drug comprises hydrocodone or a therapeutically acceptable salt thereof.
23. The method of claim 17, wherein the drug comprises oxycodone or a therapeutically acceptable salt thereof.
24. The method of claim 17, wherein the drug comprises morphine or a therapeutically acceptable salt thereof.
25. The method of claim 17, wherein the gel forming polymer comprises one or more of polyethylene oxide having average molecular weight ranging form about 300,000 to about 5,000,000, polyvinyl alcohol having a molecular weight of about 20,000 to 200,000, hydroxypropyl methyl cellulose having a molecular weight of about 10,000 to 1,500,000, and a carbomer having a molecular weight ranging of about 700,000 to 4,000,000,000.
26. The method of claim 17, wherein the gel forming polymer comprises one or more of polyethylene oxide having a viscosity in the range from about 8,800 to about 17,600 cps., polyvinyl alcohol having a viscosity in the range from about 4 to about 65 cps., hydroxypropyl methyl cellulose having a viscosity in the range from about 3600 to about 5600 cps., and a carbomer having a viscosity in the range from about 4000 to about 39,400 cps.
27. The method of claim 17, wherein the step of controlling the amount of nasal tissue irritant comprises the step of adding 1 to 5 percent by weight of one or more of poloxamer, sorbitan monoesters, glyceryl monooleates and sodium lauryl sulfate.
28. The method of claim 17, wherein the gel forming polymer comprises polyvinyl alcohol.
29. The method of claim 17, wherein the gel forming polymer comprises hydroxypropyl methyl cellulose.
30. The method of claim 17, wherein the gel forming polymer comprises polyethylene oxide.
31. The method of claim 17, wherein the step of controlling the amount of nasal tissue irritant comprises the step of adding 1 to 5 percent by weight sodium lauryl sulfate.
32. The therapeutic composition of claim 1, wherein the emetic comprises zinc sulfate at about 5 to 25 percent by weight on a solid basis.
33. A therapeutic pharmaceutical composition in unit dose form comprising
(a) an opioid analgesic;
(b) a gel forming polymer comprising one or more of polyethylene oxide having average molecular weight ranging form about 300,000 to about 5,000,000, polyvinyl alcohol having a molecular weight of about 20,000 to 200,000, hydroxypropyl methyl cellulose having a molecular weight of about 10,000 to 1,500,000, and a carbomer having a molecular weight ranging of about 700,000 to 4,000,000,000;
(c) 1 to 5 percent by weight sodium lauryl sulfate; and
(d) less than about 0.6 to 2.0 gm of zinc sulfate.
34. The therapeutic pharmaceutical composition in unit dose form of claim 33, wherein the analgesic is selected from the group consisting of alfentanil, amphetamines, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diphenoxylate, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, \u03b2-hydroxy-3-methylfentanyl, levo-\u03b1-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, methylphenidate, morphine, nalbuphine, nalmefene, o-methylnaltrexone, naloxone, naltrexone, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine and tramodol, or therapeutically acceptable salts thereof.
35. The therapeutic pharmaceutical composition of claim 33, wherein the analgesic comprises hydrocodone or a therapeutically acceptable salt thereof.
36. The therapeutic pharmaceutical composition of claim 33, wherein the analgesic comprises oxycodone or a therapeutically acceptable salt thereof.
37. The therapeutic pharmaceutical composition of claim 33, wherein the analgesic comprises morphine or a therapeutically acceptable salt thereof.
38. A therapeutic pharmaceutical composition comprising
(a) an analgesic;
(b) a gel forming polymer;
(c) a mucosal tissue irritant; and
(d) an emetic in sufficient amount to cause emesis if greater than a prescribed amount of the analgesic of the therapeutic composition is ingested.
39. The therapeutic pharmaceutical composition of claim 38, wherein the analgesic comprises hydrocodone or a therapeutically acceptable salt thereof.
40. The therapeutic pharmaceutical composition of claim 38, wherein the analgesic comprises oxycodone or a therapeutically acceptable salt thereof.
41. The therapeutic pharmaceutical composition of claim 38, wherein the analgesic comprises morphine or a therapeutically acceptable salt thereof.
42. The therapeutic pharmaceutical composition of claim 1, wherein the nasal tissue irritant comprises a surfactant.
43. The therapeutic pharmaceutical composition of claim 38, wherein the mucosal tissue irritant comprises a surfactant.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for mapping platform-based design to multiple foundry processes, comprising:
(a) predefining a slice;
(b) mapping said slice onto a first fabrication process with a first set of design rules to produce a first result;
(c) evaluating said slice with a second fabrication process with a second set of design rules to produce a second result; and
(d) comparing said first result and said second result to produce a third result.
2. The method of claim 1, wherein said slice is a RapidSlice\u2122.
3. The method of claim 1, wherein said step (d) is a hybrid analysis whereby evaluation of an element of said slice is discontinued when said element is established to be accessible in said second fabrication process.
4. The method of claim 1, wherein said step (d) is accomplished with a network-distributed processing system.
5. The method of claim 1, wherein said third result including at least one variable that is invariant in said platform-based design.
6. The method of claim 1, further comprising modifying said slice definition based on said third result.
7. The method of claim 1, further comprising optimizing a metalization process giving a final function of said slice based on said third result.
8. The method of claim 1, further comprising modifying said first fabrication process based on said third result.
9. The method of claim 1, further comprising modifying said second fabrication process based on said third result.
10. The method of claim 1, further comprising storing said third result into a database.
11. The method of claim 1, further comprising optimizing platform architecture used to predefine said slice based on said third result.
12. The method of claim 11, further comprising optimizing temporal structure of interconnect of said platform architecture based on said third result.
13. An apparatus for mapping platform-based design to multiple foundry processes, comprising:
(a) means for predefining a slice;
(b) means for mapping said slice onto a first fabrication process with a first set of design rules to produce a first result;
(c) means for evaluating said slice with a second fabrication process with a second set of design rules to produce a second result; and
(d) means for comparing said first result and said second result to produce a third result.
14. The apparatus of claim 13, wherein said slice is a RapidSlice\u2122.
15. The apparatus of claim 13, wherein said means (d) performs a hybrid analysis whereby evaluation of an element of said slice is discontinued when said element is established to be accessible in said second fabrication process.
16. The apparatus of claim 13, wherein said means (d) comprises a network-distributed processing system.
17. The apparatus of claim 13, wherein said third result including at least one variable that is invariant in said platform-based design.
18. The apparatus of claim 13, further comprising means for modifying said slice definition based on said third result.
19. The apparatus of claim 13, further comprising means for optimizing a metalization process giving a final function of said slice based on said third result.
20. The apparatus of claim 13, further comprising means for modifying said first fabrication process based on said third result.
21. The apparatus of claim 13, further comprising means for modifying said second fabrication process based on said third result.
22. The apparatus of claim 13, further comprising means for storing said third result into a database.
23. The apparatus of claim 13, further comprising means for optimizing platform architecture used to predefine said slice based on said third result.
24. The apparatus of claim 23, further comprising means for optimizing temporal structure of interconnect of said platform architecture based on said third result.
25. A computer-readable medium having computer-executable instructions for performing a method for mapping platform-based design to multiple foundry processes, said method comprising steps of:
(a) predefining a slice;
(b) mapping said slice onto a first fabrication process with a first set of design rules to produce a first result;
(c) evaluating said slice with a second fabrication process with a second set of design rules to produce a second result; and
(d) comparing said first result and said second result to produce a third result.
26. The computer-readable medium of claim 25, wherein said slice is a RapidSlice\u2122.
27. The computer-readable medium of claim 25, wherein said step (d) is a hybrid analysis whereby evaluation of an element of said slice is discontinued when said element is established to be accessible in said second fabrication process.
28. The computer-readable medium of claim 25, wherein said step (d) is accomplished with a network-distributed processing system.
29. The computer-readable medium of claim 25, wherein said third result including at least one variable that is invariant in said platform-based design.
30. The computer-readable medium of claim 25, wherein said method further comprising modifying said slice definition based on said third result.
31. The computer-readable medium of claim 25, wherein said method further comprising optimizing a metalization process giving a final function of said slice based on said third result.
32. The computer-readable medium of claim 25, wherein said method further comprising modifying said first fabrication process based on said third result.
33. The computer-readable medium of claim 25, wherein said method further comprising modifying said second fabrication process based on said third result.
34. The computer-readable medium of claim 25, wherein said method further comprising storing said third result into a database.
35. The computer-readable medium of claim 25, wherein said method further comprising optimizing platform architecture used to predefine said slice based on said third result.
36. The computer-readable medium of claim 35, wherein said method further comprising optimizing temporal structure of interconnect of said platform architecture based on said third result.
37. A computer-readable medium having stored thereon a database having a data structure, said data structure comprising:
(a) a first field containing data representing a slice definition;
(b) a second filed containing data representing a first set of design rules with which said slice definition is mapped to a first fabrication process;
(c) a third field containing data representing a second set of design rules with which said slice definition is mapped to a second fabrication process; and
(d) a fourth field containing data representing a result of computed comparison between results of said two mapping.
38. The computer-readable medium of claim 37, wherein said slice is a RapidSlice\u2122.
39. The computer-readable medium of claim 37, wherein said result of computed comparison includes at least one variable that is invariant in platform-based design used to provide said slice definition.
40. The computer-readable medium of claim 37, wherein said database is used to modify said slice definition.
41. The computer-readable medium of claim 37, wherein said database is used to optimiz a metalization process giving a final function of said slice definition.
42. The computer-readable medium of claim 37, wherein said database is used to modify said first fabrication process.
43. The computer-readable medium of claim 37, wherein said database is used to modify said second fabrication process.
44. The computer-readable medium of claim 37, wherein said database is used to optimize platform architecture used to provide said slice definition.
45. The computer-readable medium of claim 44, wherein said database is used to optimize temporal structure of interconnect of said platform architecture.